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ABSTRACT: Both HIV infection and antiretroviral drugs (ARVs) are associated with abnormalities of liver function, 
revealed by both enzymatic and non-enzymatic markers. This study evaluated the effect of HIV infection and 
antiretroviral drugs on the liver non enzymatic marker (total and direct bilirubin, total protein and albumin level) of HIV 
positive patients (pre-highly active antiretroviral therapy and those on therapies) attending the voluntary counselling 
and testing units in the state. Seventy five subjects were enrolled into the study, which constituted 25 HIV negative 
individuals (control group), 25 HIV positive patient not on antiretroviral therapy and 25 on the therapy. Bilirubin, 
albumin, total protein and CD4 cell count were determined using standard methods. Significantly (p<0.05) higher level 
of total bilirubin, direct bilirubin and total protein in the HIV positive non-treated with ARVs was observed compared to 
the control group. At the initiation of antiretroviral therapy the levels of the three parameters were lower, though 
statistically not significant except for total protein. Albumin level and CD4 cell count were significantly (p<0.05) lower 
in the non-treated group compared to the control subjects. But at the initiation of therapy the serum levels of Albumin 
and CD4 count was significantly (p<0.05) higher except for albumin level. HIV infection lowers the level of liver non 
enzymatic markers, which increase at the initiation of antiretroviral therapy. 
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INRODUCTION  
Hepatotoxicity is the most frequent (30%) toxicity of 
antiretroviral drugs, which has appeared as one of the 
leading causes of HIV related illness, death and 
treatment withdrawal (Nunez et al., 2006). The 
extensive use of antiretroviral drugs by HIV positive 
patients as well as the new antiretroviral medications 
resulted in negative impacts on the clinical outcome of 
the patients (Palellaet al., 2006).  
 
Abnormalities of liver function are frequent in HIV 
positive subjects and may be caused by other agents 
beside HIV itself; others may include: hepatitis viruses 
(major cause of death to the patients), systemic 
opportunistic infections, malignancies and ARVs 
induced hepatotoxicity (Kreisberg, 1995). The 
hepatotoxicity caused by antiretroviral drugs (ARVs) 
may be related to all the agents of the ARVs classes 
(Nickolas and Douglas, 2003). Severe and life 
threatening hepatotoxicity and fatal fulminant hepatitis 
have been reported in HIV positive patient taking mono 
therapy of antiretroviral drugs (Deniz and Tansu, 
2002). The NRTIs (the back bone of ARVs) has severe 
hepatotoxic effect particularly zidovudine mono 
therapy, which subsequently increases the risk during 
combination therapy (Nickolas and Douglas, 2003). For 
the NNRTIs, the hepatotoxicity is commonly seen with 
nevirapine therapy which typically occurs after 4-5 
months (Martínez et al., 2001). Hepatotoxicity is also a 
well known adverse effect of protease inhibitors with 
ritonavir being the most frequent cause of 
hepatotoxicity (Nickolas and Douglas, 2003).  
 
The severity of the liver disease may range from the 
absence of symptoms to liver decomposition, and the 
outcome can range from spontaneous resolution to 
liver failure and death (Clark et al., 2002 and Kramer et 
al., 2005). The severity of hepatotoxicity in HIV positive 
patients that 2% of patients are having acute hepatic 
necrosis and are dying from liver disease (Reisler et 
al., 2003). 
 
After the commencement of HAART, the reported 
incidence of severe liver toxicity ranges from 2 to 18% 
(Rodríguez-Rosado et al., 1998 and Servoss et al., 
2006). Liver failure is the major leading cause of death 
among individuals being treated with antiretroviral 
drugs (Alive and Well, 2002). Other risk of liver disease 
includes alcohol consumption, because alcohol is a 
known hepatotoxin and its use has been associated 
with an increased risk of liver dysfunction (Nuñez et al., 
2006). Furthermore, cocaine is one of the causative 
agents of hepatotoxicity via a toxic oxidative 
metabolite, which induces mitochondrial damage 
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(Campos et al., 2002). Other risk factors associated 
with liver disease include old age (Campos et al., 
2002), female gender (Martín-Carbonero et al., 2003), 
first exposure to antiretroviral treatment (Wit et al., 
2002) and significant CD4 cell gains following HAART 
initiation (Sulkowski et al., 2002).  
 
Being antiretroviral drugs the only mainstay for 
treatment of HIV infection as well as it’s widely 
reported hepatotoxic effect, we assessed the effect of 
the both HIV infection and antiretroviral drugs on liver 
non enzymatic markers of HIV positive patients 
attending the ART centre of Specialist Hospital, 
Sokoto, Nigeria. 
 
MATERIALS AND METHODS 
Experimental Design 
The study was conducted at antiretroviral therapy 
centre (ART) of Specialist Hospital, Sokoto, Nigeria. A 
total of 75 patients were enrolled into the study, which 
comprised 25 HIV negative subjects (blood donor and 
control), 25 HIV positive non treated with ARVs and 25 
patients treated with ARVs. Inclusion criterion for the 
study includes: HIV-positive patients not on treatment 
and those on treatment for one year or less, individuals 
between the ages of 15-60 year old, individuals with no 
physical sign of metabolic syndrome and patient who 
are hepatitis (A, B, or C) negative. 
 
Ethical Clearance 
Ethical clearance was obtained from the research and 
ethical committee of Specialist Hospital, Sokoto and all 
patients were informed using a standard informed 
consent form. 
 
Method used in assessment of parameters 
Bilirubin determination: The colorimetric method of 
Jendrassik and Gorf (1938) was adopted. Bilirubin 
reacts with diazotized sulphanilic acid in alkaine 
medium to form a blue coloured complex. Bilirubin is 
determined in the presence of caffeine which releases 
albumin bound bilirubin by reacting with diazotized 
sulphanilic acid. 
 
Albumin determination: The dye binding technique 
utilizing bromocresol green (BCG) as modified by 
Biggs and Doumas (1971) as employed. Albumin binds 
the indicator bromocresol (BCG) in an acidic medium 
resulting in the formation of a blue green albumin BCG 
complex. The coloured complex produced is 
proportional to the concentration of albumin in the 
serum. 
 
Total Protein determination: This was determined 
using the method of Doumas (1975). Cupric ions, in an 
alkaline medium react with the peptide bonds of protein 
molecules, forming a blue violet coloured complex. The 
intensity of coloured complex produced is proportional 
to the amount of protein present in the serum. 
CD4 Cell Count: BD FACS count system automated 
analysis was used in accordance with the method of 
Cassenset al. (2004). 
 
Analysis 
Graph Instat pad version 3.02 (Graph pad Corp., San 
Diego, USA) was used for statistical analysis. 
Descriptive statistics and analysis of variance 
(Benferroni compare all columns) was used to test for 
the level of significance between mean. A P value < 
0.05 was taken as statistically significant. 
 
RESULTS 
In all the two groups of HIV positive subjects, the result 
show that most of the patients are at the age of 20 to 
39 year having 64% and 84% in the non-treated group 
and treated subjects respectively. Furthermore, 28% 
and 12% of the HIV positive patients were within 40-59 
years of age as shown in the non-treated and treated 
subject respectively (Table 1). 
 
In the HIV positive patient, 56% and 64% in the non-
treated and treated groups respectively were females. 
Males constituted 44% in the non-treated group and 
36% in the treated group (Table 1). 
 
The result further shows that 52% and 48% of the 
females in the non-treated and treated subjects 
respectively were mostly housewives (married) 
followed by single (16% and 32%) and widows (20% 
and 12%) in the non-treated and treated group 
respectively. 
 
In the HIV positive non-treated with antiretroviral drugs, 
56% of the patients were in clinical stage I of the 
infection followed by 28% in the stage II. For the 
treated subjects, majority of the patients (44%) enrolled 
in to the study were in the stage II of the disease, 
followed by 36% been in the clinical stage I (Table 1). 
The total protein, total bilirubin, direct bilirubin of all the 
25 HIV positive patients non-treated with antiretroviral 
drugs were significantly (P<0.05) higher than the 




control group. However, in the treated subjects the 
level of total bilirubin, direct bilirubin and total protein 
were lower compared to the non-treated group, though 
the increase is statistically insignificant (P<0.05) except 
for the total protein. Albumin levels and CD4 cell count 
of the non-treated subjects, show a significantly lower 
(p<0.05) compared to the control group. But at the 
initiation of antiretroviral therapy, the level of albumin 
and CD4 cell count in the treated subject were higher 
though not statistically (P<0.05) significant except for 
the CD4 cell count (Table 2). 
 
Table 1: Demographic Information of the Study Subjects in Sokoto. 
Parameters Control HIV+ Non-treated HIV+ Treated 
Age (years)    
1-19 1 (4%) 2 (8%) 1 (4%) 
20-39 16 (64%) 16 (64%) 21 (84%) 
40-59  8 (32%)  7 (28%)  3 (12%) 
Gender    
Male 20 (80%) 11 (44%) 9 (36%) 
Female 5 (20%)  14 (56%) 16 (64%) 
Marital Status    
Single 15 (60%) 4 (16%)  8 (32%) 
Married  5 (20%) 13 (52%) 12 (48%) 
Divorced 3 (12%)  3 (12%)  2 (8%) 
Widowed 2 (8%)  5 (20%) 3 (12%) 
Clinical Stage    
Stage I  - 14 (56%) 9 (36%) 
Stage II  - 7 (28%) 11 (44%) 
Stage III - 2 (8%) 3 (12%) 
Stage IV  - 1 (4%) 2 (8%) 
KEY: n= Sample size (25 per group). 
 
Table 2: Biochemical Effect of HIV and ARVs on Liver non Enzymatic Indices and CD4 Cell Count of Control, HIV 
Positive non-treated and HIV Positive treated used in the Study. 
Parameters Control HIV+ Non-treated HIV+ Treated 
T-Bilirubin (mg/dl)  0.56±0.04* 0.79±0.04* 0.69±0.04 
D-Bilirubin (mg/dl) 0.27±0.02* 0.43±0.01* 0.39±0.01 
T-Protein (g/dl)  6.35±0.16* 8.75±0.15*a  6.95±0.28*a 
Albumin (g/L) 9.93±1.91*  27.55±2.47* 30.40±0.89 
CD4 Cells (cell/µL) 965.76±25.93* 308.88±25.07*a 442.08±49.43a 
KEY: n= Sample size (25 per group),  Values are expressed as Mean ± SEM;  
Values with the same superscript in column are statistically significant (P < 0.05);  
D-Bilirubin: Direct Bilirubin, T-Bilirubin: Total Biliburin, T-Protein: Total Protein. 
 
DISCUSSION 
In the current study, the effects of HIV infection and 
antiretroviral drugs (ARVs) on liver non enzymatic 
markers which include total and direct bilirubin, total 
protein, albumin and CD4 cell count were investigated.  
Majority of the HIV patients were between the age of 20 
to 39 years old, constituting 64% and 84% of the HIV 
positive non-treated group and HIV positive treated 
subjects respectively. Many factors may contribute to 
the higher HIV infection in the middle age people 
among which include their physical strength and high 
sexual activity which is major route for the HIV 
transmission. The finding also agrees with survey by 
Federal Ministry of Health, Nigeria (2003) and UNAIDS 
(2004).  
 
Females form the majority of HIV patients, constituting 
56% and 64% of HIV positive non-treated and treated 
subjects respectively. This may be due to practiced of 
some traditional practices like female genital mutilation 
(FGM) and having multiple sex partners as may occur in 
polygamous relationships of paramount importance is 
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the lack of western knowledge, in addition to other 
socioeconomic factors like increase in the 
commercialization of sex (FMOH, 2003). Survey by 
UNAIDS (2010), show that the rate of women infected 
with HIV rose from 43% in 1999 to 50% in 2010. The 
report further revealed that in Sub-Saharan Africa, 
women comprised 59% of the adult living with HIV 
infection in 2010. Moreover, another study conducted 
by the Federal Ministry of Health (FMOH) in 2003 and 
2005 reported that in northern Nigeria over 40% of the 
married females are on polygamous system of marriage 
with also over 24% of males on the same marriage 
system. In 2010 National HIV sero-prevalence sentinel 
survey by the FMOH reported that majority of HIV 
infected people in Nigeria were women. The high 
practice of polygamous marriage in the state may be 
the core factor for the high rate of infection among 
women.    
 
Our results further reveal that 52% and 48% of the HIV 
positive non-treated group and treated subject 
respectively were married. The result was contrary to a 
2010 sentinel survey report by the FMOH which showed 
that widows have the highest rate (6.9%) followed by 
single (5.6%) and married with 4.9% (FMOH, 2010). 
The possible reason for this may be due to the fact that 
most of the men in the state possess more than one 
wife and consequently one infected husband is likely to 
infect two or more of his wives. Before the introduction 
of antiretroviral therapy most of the infected men die 
with the infection leaving their spouse (s) behind, hence 
the high number of widows than married. With the 
introduction of ARVs, the rate of death has drastically 
reduced, which makes the rate of married men and 
women higher than the widows.  
 
Our study show an significant (P<0.05) increase in 
serum level of total, direct bilirubin and total protein in 
HIV positive patients not on treatment when compared 
with treated.  
 
High level of bilirubin in the blood may be as a result of 
either the body system is producing excess bilirubin or 
the liver is unable to eliminate the excess bilirubin 
produced by the system (Naik, 2010). An elevated level 
of bilirubin in the blood of HIV positive patients may 
indicate liver disease due to HIV infection or 
antiretroviral drugs (Onwuliri, 2004). 
The finding of this study was in line with a study by 
Onwuliri (2004) who reported that total and 
unconjugated bilirubin concentration were significantly 
higher in HIV infected subjects compared to control. 
Another study by Ayelagbe et al. (2014) reported 
significant increase in the level of total bilirubin in 
HAART naive subject compared to control group. 
 
Many documented studies revealed that antiretroviral 
drugs induce liver damage through an elevation in the 
level of bilirubin. Our finding do not support these 
claims, as the levels decreased in treated subjects 
when compared with non treated group, though the 
increase is not statistically significant. The result of this 
finding was also contrary to the study by Ayelagbe et al. 
(2014) as reported significant increase in total and 
conjugated bilirubin of HIV positive on HAART subjects 
compared to HAART naïve subjects. 
 
HIV infection is associated with remarkable alteration in 
the levels of proteins in the liver (Treitinger et al., 2001). 
Protein abnormalities have been reported in all the 
stages of HIV infection (Grunfeld et al., 1992 and 
Jaboor et al., 1999). Jaboor et al. (1999) reported that 
acute phase response to infection is associated with an 
increase in protein turnover and remarkable 
degradation of protein. HIV infection induces leukocyte 
proliferation, increase in the synthesis of cytokines and 
immunoglobulin which was shown to contribute to 
protein turnover (Fleck, 1989). 
 
Fuhrman et al. (2004) and Banh (2006) reported that 
serum total protein in HIV positive patients decreases 
during inflammation, which returns to normal level after 
resolution. Banh (2006) reported that the level of protein 
can be affected by factors like capillary permeability and 
drugs (like ARVs). 
 
Furthermore, the result of this finding show that albumin 
level and CD4 T-cell count of HIV positive non-treated 
with ARVs has significantly (p<0.05) decreased when 
compared to the control group. Comparing the level of 
these parameters of the non-treated group and treated 
subjects, the result revealed an increase in the level of 
albumin and CD4 cell count in the treated group 
compared to non-treated group, though only for CD4 cell 
count was found to be statistically significant (p<0.05). 
 
Albumin synthesized by the liver helps maintain the 
amount of blood in the vein and arteries. Decrease in 
albumin level (hypoalbuminemia) in HIV positive 
patients may be due to increase in transcapillary 
escape rate and elevated catabolic rate against 




decrease in hepatic synthesis caused by HIV infection 
(Fleck et al., 1989). 
 
Immune system activation as a result of HIV infection 
leads to inflammation (either acute or chronic) in HIV 
infected patients, which in turn lowers the levels of 
albumin through imposing liver to channels it to other 
proteins needed for immune response (Naik, 2010). 
Both HIV infection and antiretroviral drugs cause kidney 
disease, cardiovascular disease, and arthritis, which are 
potential source of chronic inflammation in people living 
with HIV infection (Fuhrman et al., 2004).  
 
CONCLUSION 
Total bilirubin, direct bilirubin and total protein are 
significantly (P<0.05) higher in the HIV positive non-
treated with ARVs compared to the control group. At the 
commencement of antiretroviral therapy the levels of 
these three parameters were lower, though statistically 
not significant (P<0.05) except for total protein. Albumin 
level and CD4 cell count were significantly (p<0.05) 
lower in the non-treated group compared to the control 
subject. But at the beginning of the therapy they serum 
levels of Albumin and CD4 cell count were significantly 
(p<0.05) higher except for albumin level. HIV infection 
lowers the level of liver non enzymatic markers, which 
antiretroviral drugs increase. 
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